左西孟旦治疗失代偿性心力衰竭患者临床疗效分析.docVIP

左西孟旦治疗失代偿性心力衰竭患者临床疗效分析 　　【摘要】 目的 分析左西孟旦治疗失代偿性心力衰竭患者的临床疗效。方法 158例失代偿性心力衰竭患者， 根据治疗方法不同分为对照组（77例）和观察组（81例）。对照组采用常规心力衰竭治疗， 观察组在此基础给予左西孟旦治疗。观察比较两组临床疗效及不良反应情况。结果 观察组与对照组血K+[（4.89±0.41）、（4.22±0.58）mmol/L]、血Ca2+[（2.48±0.14）、（2.23±0.26）mmol/L]、射血分数[（39.25±7.28）%、（33.84±6.03）%]及每搏输出量[（72.54±24.26）、（64.33±23.16）ml]较治疗前均上升， 且观察组上升程度高于对照组（P0.05）。治疗后， 观察组各年龄段氨基末端利钠肽前体（NT-proBNP）水平[（863.58±105.43）、（1637.49±362.23）pg/ml]优于对照组（P0.05）。观察组不良反应发生率为4.94%， 低于对照组的16.88%（P0.05）。结论 采用左西孟旦治疗失代偿性心力衰竭， 其疗效显著， 能有效提高患者血液输送功能且能减少不良反应， 具有推广价值。 　　【关键词】 失代偿性心力衰竭；左西孟旦；疗效 　　DOI：10.14163/j.cnki.11-5547/r.2016.25.014 　　【Abstract】 Objective To analyze clinical effect by levosimendan in the treatment of decompensated heart failure patients. Methods A total of 158 decompensated heart failure patients were divided by different treatment measures into control group （77 cases） and observation group （81 cases）. The control group received conventional treatment for heart failure， and the observation group received additional levosimendan. Clinical effects and adverse reactions were observed and compared between the two groups. Results Both groups had higher serum K+ [（4.89±0.41） and （4.22±0.58） mmol/L]， serum Ca2+ [（2.48±0.14） and （2.23±0.26） mmol/L]， ejection fraction [（39.25±7.28）% and （33.84±6.03）%] and stroke volume [（72.54±24.26） and （64.33±23.16） ml] than those before treatment， and the observation group had higher increased degree than the control group （P0.05）. After treatment， the observation group had better N-terminal pro brain natriuretic peptide （NT-proBNP） levels in all age groups [（863.58±105.43） and （1637.49±362.23） pg/ml] than the control group （P0.05）. The observation group had lower incidence of adverse reactions as 4.94% than 16.88% of the control group （P0.05）. Conclusion Implement of levosimendan shows precisely curative effect in treating decompensated heart failure， and it can effectively improve blood transport function and reduce adverse reactions in patients. This method contains